מקורות וסימוכין

    1. Bonjesta Drug registration, ministry of health.
    2. Bonjesta patient leaflet as approved by the Israeli Ministry Of Health
    3. ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Obstetrics & Gynecology 2018;131:e15-e30
    4. https://motheriskinternational.com/bonjesta-the-first-dual-release-combination-of-doxylamine-pyridoxine-for-morning-sickness/
    5. Bonjesta Physician leaflet as approved by the Israeli Ministry Of Health
    6. Diclectin® Prescribing Information.
    7. APGO Continuing Series on Women’s Health Education. Nausea and Vomiting of Pregnancy.
    8. Costantine, M. M., et al. Determinants of adherence to delayedrelease doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. Ther Drug Monit. 2012; 34:569-573.
    9. surrounding us. Koren, G. Safety considerations of treatment options for nausea and vomiting in pregnancy. Expert Opin Drug Saf. 2017; 16 (11):1227-1234.
    10. G. Koren C. Maltepe How to survive Morning Sickness Successfully.
    11. S. Madjunkova et al, The Delayed-Release Combination of Doxylamine and Pyridoxine (Diclegis_/Diclectin_) for the Treatment of Nausea and Vomiting of Pregnancy Pediatr Drugs 2014
    12. Ebrahimi N, Maltepe C, Bournissen FG, Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. J Obstet Gynaecol Can. 2009;31(9):803-807

    13. Food and Drug Administration. Center for Drug Evaluation and Research: NDA 209661, Approval Package 2016.